Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
Agios Pharmaceuticals, Inc. PYRUKYND is the only medicine approved in the UAE for adults with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia NewBridge Pharmaceuticals, a regional specialty company, will continue to manage commercialization of PYRUKYND in the Gulf region CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has approved PYRUKYND ® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. With this approval, PYRUKYND becomes the only medicine approved in the UAE for this patient population. “For too long, thalassemia patients have endured debilitating and often li
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIOPR Newswire
- Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction [Yahoo! Finance]Yahoo! Finance
- Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab EmiratesGlobeNewswire
- Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
AGIO
Earnings
- 2/12/26 - Miss
AGIO
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- AGIO's page on the SEC website